Dr. John Cush RheumNow
4 years 4 months ago
Save the date! Join us on May 17th for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.
https://t.co/s7r09y5KNG https://t.co/0KYRPwGHsV
Dr. John Cush RheumNow
4 years 4 months ago
Bimekizumab's Favorable Safety Profile in Psoriasis
A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis.
https://t.co/84zS8VET6B https://t.co/aLvLmmTc93
Janet Pope Janetbirdope
4 years 4 months ago
#ClinicalPearl Autoantibodies in #Sjogren’s Syndrome include CCP and anticentromere - think of overlaps with #rheumatoid arthritis or lcSSc limited cutaneous systemic sclerosis #scleroderma #CCR22 #CCR2022 @RheumNow https://t.co/vrdbv640B5
Dr. John Cush RheumNow
4 years 4 months ago
Risk factors for readmission among 132,400 #SLE hospitalizatiions included young SLE, AIHA (OR 1.86) GN (OR 1.41) pericarditis (OR 1.4), CHF(OR 1.38), Medicare (OR 1.2), Medicaid (OR 1.26). Most Readm Dxs were Sepsis, CHF, pneumonia https://t.co/Nr9bCGDaw0 https://t.co/THO6KT6dWV
Join medical resident Siobhan Deshauer, MD, as she visits three hospitals for inpatient rheumatology. Watch the video or read the partial transcript below. Siobhan Deshauer, MD, is an internal medicine resident in Toronto. Before medicine, she was a violinist, which is why her YouTube channel is called Violin MD.
Dr. John Cush RheumNow
4 years 4 months ago
Systemic Sclerosis patients with Digital Ulcers used significantly more healthcare resources per year. Study of 104 SSc pts; w/ DU's had more severe disease, more tests, More HCP/Rheum visits, etc (p˂0.05) https://t.co/wWvrOye92c https://t.co/HsZfSrf5CV
Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.
A crowd sourced, WikiGuidelines approach to clinical treatment guideline development for pyogenic osteomyelitis yielded 7 important clinical questions, 2 clear treatment recommendations and 5 topic reviews to inform future treatment or investigations.
Dr. John Cush RheumNow
4 years 4 months ago
We had a great TNR this week. Playback now available in case you missed it.
This webinar presented excerpts from these lectures along with Q & A
Psoriatic Arthritis Guidelines
Drug Targeting in PsA
PsA Registries and Real World Data
https://t.co/al17KLQm0j https://t.co/O4SvMU37Lg
Dr. John Cush RheumNow
4 years 4 months ago
Early inflammatory arthritis pts (n=35,807; 86% White & 5,164 ethnic minority). Whites & minorities were equally seen by rheum <3 wks & started on Rx < 6wks, <inorities had less remission @3 mos (OR 0.79) or recv MTX 1st or steroids(0.68-0.63) https://t.co/rK7GLt5n1X https://t.co/uUwBBCnyGL
Dr. John Cush RheumNow
4 years 4 months ago
Doctor Survey: how many Rheumatic/Autoimmune pts do you have on Evusheld (PrEP)?
Dr. John Cush RheumNow
4 years 4 months ago
ASCORE: Seropositivity Favors Abatacept Drug Survival
The ASCORE study evaluated efficacy, safety, and drug retention (durability) of ABA in moderate-to-severe RA and found consistently better ABA durability in those who were seropositive.
https://t.co/n855mvkaoT https://t.co/1nCjL89Bfw
Dr. John Cush RheumNow
4 years 4 months ago
Study of 218 primary APS w/ Thrombocytopenia in 74 (34%) - such pts had signif. more visceral venous thromboses (13.5% vs. 3.5%), hemolytic anemia (27% vs. 12%), low C3/C4 (26% vs 11%), & higher pregnancy morbidity (HR 8.0, p = 0.0006) https://t.co/U9drB3gWq2 https://t.co/0EwItMO9N1
Dr. John Cush RheumNow
4 years 4 months ago
Making You the Expert of You! (Smart Rules for Patients)
You’ve scheduled an appointment with your medical provider - how do you make the most of it?
https://t.co/62mTqk4ksL https://t.co/gr7Hvt7EI3
A 2-year safety study of bimekizumab, the dual IL-17A/F inhibitor, plaque psoriasis patients showed bimekizumab (BMK), to be effective, well tolerated, with no new safety concerns other than a modest risk of oral candidiasis.
